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A B S T R A C T
The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, reg-
ulation and clinical research. However, without a biological rationale for these disorders, drug development has
stagnated. The recently EU-funded PRISM project aims to develop a quantitative biological approach to the
understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of
better treatments. By combining clinical data sets from major worldwide disease cohorts and by applying in-
novative technologies to deeply phenotype stratified patient groups, we will define a set of quantifiable biolo-
gical parameters for social withdrawal and cognitive deficits common to Schizophrenia (SZ), Major Depression
(MD), and Alzheimer’s Disease (AD). These studies aim to provide new classification and assessment tools for
social and cognitive performance across neuropsychiatric disorders, clinically relevant substrates for treatment
development, and predictive, preclinical animal systems. With patients and regulatory agencies, we seek to
provide clear routes for the future translation and regulatory approval for new treatments and provide solutions
to the growing public health challenges of psychiatry and neurology.
1. Introduction
1.1. Brief history of drug discovery for neuropsychiatric disorders
Mankind has been using psychoactive substances for millennia both
for recreation and to alleviate suffering. Indeed, at least an acknowl-
edgement of abnormal psychiatric behaviour can be definitively traced
back at least as far as classical times and pharaonic Egypt. However,
attempts to understand these disorders with the aim of effective and
systematic treatment really only emerges in the late 1800′s; for de-
mentia praecox and depressive states. Effective treatments for the
symptoms associated with these disorders did not emerge until after
World War II. The first neuroleptic, chlorpromazine, was introduced in
1952 (Rhone Poulenc) shortly followed by the first tricyclic
antidepressant imipramine (Roland Kuhn & Geigy) all from anti-hista-
mine chemistry. In parallel with the newly available pharmaceuticals
the nosology of psychiatric disorders took a major step forward in the
same decades. In 1949 the International Statistical Classification of
Diseases (ICD) included a section on mental disorders for the first time
while DSM-1 (Diagnostic and Statistical Manual of Mental Disorders)
emerged from efforts by the American Military to accurately classify
psychiatric disorders. Current nosography is still largely based on the
reliability improvement obtained with DSM-3 (American Psychiatric
Association, 1980), which was however based on clinical observation
only.
These advances led to huge improvements in society’s perception of
mental disorders and the ability to effectively treat the symptoms but,
neither the classification nor the treatment was based on any
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understanding of biological cause. Indeed, the mechanisms by which
the drugs acted was effectively a mystery at this point. The fact that we
now have hypotheses relating to the role of dopamine in schizophrenia
and serotonin in depression largely results from a careful dissection of
the pharmacological mechanisms of molecules of proven clinical ben-
efit based on serendipity rather than either a direct mechanistic study of
the human condition or from the consequence of rational drug design.
Indeed, it can be argued that we need to wait 30 years from this re-
volution for the first drugs to be taken to market as a consequence of
rational drug discovery (Fluoxetine – marketed by Eli Lilly from 1988).
The consequence of this process is that we have become very good at
developing “me too” drugs where “psychosis”, for instance, has become
a symptomatic surrogate label for a disease process that responds to
dopamine antagonism. It is now clear though that the reality of the
biology that leads to psychosis is far more complex making the label
progressively less useful.
It is important to remember that most mental health conditions are
still classified, diagnosed, and prescribed for solely based on the
symptoms observed and that it has not been until very recently that we
have had a neuroscience based nomenclature for psychotropic drugs
(Caraci et al., 2017; Zohar et al., 2015). This is in contrast to many
somatic conditions, such as diabetes, hypertension or cancer. Further
we now recognize that many different neuropsychiatric diseases share
symptoms, such as cognitive deficits, psychosis, anhedonia, or social
withdrawal, which makes it difficult to understand what the underlying
pathophysiological mechanisms are. For example, we do not really have
an idea how, if at all, the biological cause for social withdrawal in
Alzheimer’s disease differs from that in schizophrenia.
This lack of understanding of the root pathophysiological causes of
neuropsychiatric disorders is one of the reasons behind the dramatic
slowdown in the discovery and development of new drugs to treat these
disorders. Modern drug discovery is now very much driven by hy-
potheses derived from a mechanistic understanding of the disorders for
which new therapies are being developed. Without robust hypotheses
areas become deprioritized as executing an effective drug discovery
programme, as demonstration of mechanistic proof of concept and
clinical efficacy proofs difficult. For neuropsychiatric diseases, this
approach has been hampered not only by the missing link between
diagnostic criteria and underlying pathophysiological causes but also
by suitable instruments to assess the brain’s connectivity and circuitry
to a sufficient extent. The emergence of new ways of measuring brain
activity (e.g. functional Magnetic Resonance Imaging (fMRI) of the
brain, which registers blood flow to functioning areas of the brain, or an
electroencephalogram (EEG) to assess evoked related potentials of the
brain) is opening the door to the development of novel mechanistic
hypotheses based on a new understanding of the brain systems and
neural circuits perturbed in different mental health conditions. These
hypotheses can then form the basis for improved nosology to describe,
classify and diagnose disorders, guide prescribing, stimulate novel drug
discovery, identify improved regulatory categories and improve the
efficiency of clinical trials.
1.2. RDOC’s initiative
In view of the above limitations, in 2009, the National Institute of
Mental Health (NIMH) proposed a new research classification system:
the Research Domain Criteria (RDoC) (Cuthbert and Insel, 2010). It was
clear that despite the best of intentions, DSM-5 has been unable to in-
corporate neuroscience into its clinical diagnostic criteria, mostly be-
cause neuroscience (e.g., genetics, neuroimaging) and behavioural
science data map poorly to current symptom-based disorders (Cuthbert
and Insel, 2013). With a humble perspective, the RDoC spirit is that we
cannot resolve complex problems with simple common solutions, and
we need to dissect the different levels of complexity from genes to
behaviour, subjective experiences, or even paradigms. This new re-
search classification is based on dimensions of observable behaviour
and neurobiological measures to identify fundamental components that
may span multiple disorders. The RDoC framework needs to integrate
many different levels of data to develop a research approach in order to
classify a mental disorder based on pathophysiology and link it more
precisely to interventions for a given individual in a precision medicine
paradigm (Insel and Cuthbert, 2015).
It is clear that a number of treatment modalities, including phar-
maceutical and psychosocial or behavioural treatments, as well as
medical devices, have been shown to be efficacious in a broad range of
disorders (e.g., selective serotonin reuptake inhibitors to improve mood
in many different categorical disorders or benzodiazepines for anxiety
in a variety of DSM or ICD disorders). This would argue in favor of
identifying fundamental components that may span multiple disorders
(e.g., executive function, affect regulation, social withdrawal) and for
the development of reliable and valid measures of those components for
use in drug development or clinical trials. The RDoC proposes to focus
on a novel mechanism relevant to a clinical problem defined as a do-
main or construct (e.g., social withdrawal) regardless of DSM/ICD di-
agnosis and to enroll patients in clinical trials based on deficits in that
mechanism and not on DSM/ICD diagnosis. In order to do that, it is
important to assess the extent to which the domain has the same or
different biological underpinnings across the different categorically
defined disorders.
1.3. Technical advances
1.3.1. Preclinical research
As there is a growing philosophical concern about trying to “model”
complex, possibly species specific, disorders such as schizophrenia and
depression the advent of technologies allowing high resolution phy-
siological monitoring offer a potential alternative approach. These ap-
proaches include electrophysiology, imaging of structure and function,
neurochemistry, which are in many cases now applicable in real world
spontaneous or controlled behavioural states. For example, analysis of
EEG in a variety of modalities in man is an example of where it is now
possible to provide validated pre-clinical homologous techniques. To
extend the example an auditory evoked response (AER) can be mea-
sured now in both man and freely moving rat or mouse. The relation-
ship between the electrode placements and the underlying neuroana-
tomical structures is equivalent. The profile of the response is near
identical when scaled temporally to compensate for the differences in
neuronal path length, and the perturbations induced by drug adminis-
tration are highly equivalent (Fig. 1). If, therefore, using a pallet of such
techniques and parameters a quantitative description of the abnorm-
alities of specific aspects of a particular disorder can be determined we
have a real chance of directly back-translating human findings in ani-
mals, and to expand our neurobiological knowledge.
These advances have been arrived at through the application of;
microelectronics, improved understanding and ability to deploy bio-
sensors, dramatically more powerful data acquisition and analysis soft
and hardware. Further, approaches are now possible where these
technologies can be combined with more traditional behavioural
techniques to allow different “states” and “circuits” to be probed in a
hypothesis driven manner. In parallel the ability to manipulate the
brain in a disease-relevant many is again undergoing a similar revolu-
tion. A few examples of these advances include; a better understanding
of the application of transgenic technologies, inducing neurodegen-
erative disease states using clinically identical protein triggers, phar-
maco- and opto-genetics. Taken together we have a powerful transla-
tional toolbox to deploy if we can identify meaningful and
discriminating parameters in the clinical setting to back-translate from.
1.3.2. Clinical research
The advances over the last decade in terms of clinical mental health
research are numerous. Three potentially ‘game-changing’ innovative
techniques will be highlighted. First, brain imaging techniques such as
M.J. Kas et al. Neuroscience and Biobehavioral Reviews 97 (2019) 3–9
4
structural or functioning Magnetic Resonance Imaging (sMRI or fMRI)
but also electroencephalogram (EEG) have become more widely avail-
able and applied in mental health research in the last decade (Milham
et al., 2017). This has opened the possibilities to examine structure and
activity of the brain, thereby providing opportunities to better under-
stand the role of the brain in mental health conditions and interven-
tions. Second, the system biology approach has become more advanced
and applicable to clinical mental health research (Alawieh et al., 2012),
which allows for more detailed insights in the pathophysiology of
mental health conditions. It is now technically possible and cost-effi-
cient to apply various ‘-omics’ assessments in blood, saliva, brain or
other tissue materials. These methods allow a further exploration of
gene-expression, epigenetics, metabolomics and proteomics patterns,
and their interactions, at a more extensive scale, and relate these to
mental health conditions. Third, the application of e-Health and m-
Health technology is another technical innovation with a potential big
impact on mental health research. This allows us to both passively and
actively follow persons over time through ambulatory assessments.
Through this technique, innovative assessments of the impact of daily
routines and life events become possible, and individual mental health
symptom patterns as well as social and physical activaty can be tracked
over time. Such data allow for more detailed assessments of neu-
ropsychiatric health in a person’s natural environment and therefore for
more personalized outcome monitoring and potential intervention
strategies (Myin-Germeys et al., 2009).
1.3.3. Data analyses
Application of new clinical methods, as described above, can gen-
erate innovative ‘big data’ in the field of neuropsychiatry. New com-
putational neuroscience is necessary to undertake either theory-driven
or data-driven approaches to quantitatively delineate the underlying
mechanisms of neuropsychiatric disorders. The data-driven approach is
an emerging field in computational neuroscience seeking to identify
disorder-specific features among high-dimensional multi-modal big
data. Various machine-learning techniques can be applied to e.g. neu-
roimaging and – omics data and the extracted disorder-specific features
can be used for automatic intermediate phenotype status. Emerging
techniques – such as those that estimate normative models for map-
pings between biology and behaviour – can provide new ways to parse
the heterogeneity of underlying neuropsychiatric diseases (Marquand
et al., 2016). An inherent risk to innovative ‘big data’ analyses is that of
producing chance findings when there is no appropriate validation and
replication applied. However, when appropriately utilized, these tech-
niques provide promising ways to substantially increase our under-
standing of the underlying pathophysiology of (clusters or dimensions
of) neuropsychiatric disorders. They have great promise in establishing
a link between phenomenological and pathophysiological aspects of
neuropsychiatric disorders, thereby potentially recasting current no-
sology in more biologically meaningful dimensions.
2. Quantitative biology to neuropsychiatry
2.1. Conceptual outline of the approach
The current classification scheme for the diagnosis of neu-
ropsychiatric disorders separates each disease into non-overlapping
diagnostic categories. This separation is not based on their underlying
aetiology but on convention based clustering of qualitative symptoms of
the disorder. While these diagnostic categories are sufficient to provide
the basis for general clinical management, they do not describe the
underlying neurobiology that gives rise to individual symptoms. The
ability to precisely link these symptoms to underlying neurobiology
would not only facilitate the development of better treatments, it would
also allow physicians to provide patients with a better understanding of
the complexities of their illness facilitating improved management. To
realise this ambition, a paradigm shift is needed to raise awareness and
to build an understanding of how neuropsychiatric diagnoses can be
based on quantitative biological parameters. However, the main diffi-
culty in the construction of biologically valid diagnoses is the lack of
objective biomarkers. Moreover, the uncertain relationship between
diagnosis and underlying aetiology has created difficulties for aetiolo-
gical research and made the generation of appropriate disease models
and development of targeted treatments very difficult. As aetiological
research progresses, there has been a rethinking of these diagnostic
boundaries and their usefulness in treatment and classification of
neuropsychiatric disorders. This is partly based on the notion that there
is more aetiological overlap between psychiatric and neurodegenerative
disorders than previously thought, and that they may better be de-
scribed as domains of cross-disorder-related traits rather than separable
categories (Kas et al., 2007; Insel and Cuthbert, 2015).
2.2. Implementation in the PRISM project
Recently, the PRISM (Psychiatric Ratings using Intermediate
Stratified Markers) project was funded through the EU-Innovative
Medicine Initiative (IMI) to develop a quantitative biological approach
to the understanding and classification of neuropsychiatric diseases to
accelerate the discovery and development of better treatments for pa-
tients. In PRISM, patients with a range of neuropsychiatric symptoms
will be assessed using several analytical platforms to parse current
heterogeneous syndromes into homogeneous clusters. Furthermore, the
project will develop deeper understanding of the quantitative biology of
social withdrawal using clinical data from Schizophrenia (SZ), Major
Depression (MD) and Alzheimer’s Disease (AD) patients and by estab-
lishing a network of pre-clinical research sites able to perform high
quality back-translation studies. This way, PRISM implements an im-
portant call for integration of research across traditionally defined
psychiatric and neurological disorders. Finally, first steps will be un-
dertaken to develop the regulatory path for social withdrawal across
Fig. 1. The morphological similarities between standard tone re-
sponses in humans (a) and rats (b). Rat evoked responses latencies
were significantly shorter than their human counterpart, whilst the
amplitude of responses were smaller in humans reflecting the use of
scalp EEG rather than scull screws in rat. Data are from the placebo
arm of analogous human and rat within-subject PK/PD crossover
studies (data held on file at Eli Lilly and Co). In both trials, the
standard tone presented had a frequency of 1000 Hz, duration of
50ms with a 5ms rise/fall time, was 90 dB loud and 90% likely to
occur. The human trial occurred over 5.5 min resulting in 300 stan-
dard tone stimuli. In the rat trial 1080 stimuli presented were pre-
sented over 20min in order to ensure sufficient time spent in wake-
fulness during the trial and 300 responses randomly selected when
subjects were determined to be awake (via EEG/EMG). Results pre-
sented as mean and standard error (Human N=12, Rat N=16).
P1–the first positive wave following the stimulus (often referred to as
P100 in humans), N1–the first negative wave following the stimulus
(often referred to as N100 in humans) and P2–the second positive wave following the stimulus (often referred to as the P200) in humans.
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disorders (Fig. 2).
2.3. Key areas for PRISM implementation
The challenge of the PRISM project was to identify a target di-
mension which satisfies a set of eligibility criteria, i.e. a target that is
independent from clinical psychiatric and neurological diagnoses, has a
large epidemiological impact, has at least some known biological de-
terminants, for which an advance of knowledge of the biologic de-
terminants is realistic and that could be the target of possible specific
innovative treatments. In the PRISM project, social withdrawal
(Porcelli, in this issue) was identified as an innovative investigational
domain that matches the proposed criteria.
While the spectrum of neuropsychiatric disorders is heterogeneous,
they largely share the expression of negative symptoms, in particular
social withdrawal (Peralta et al., 1992; Reichman and Negron, 2001;
Winograd-Gurvich et al., 2006). Indeed, social withdrawal is one of the
first indicators of emerging psychiatric disorders such as SZ and MD and
neurological disorders such as AD. It is characterized by the withdrawal
of the individual from their social networks established in work places
and friendship circles. Although social withdrawal is a multi-de-
termined complex behaviour, which can be modulated by several fac-
tors – such as personality traits, disability status, aging process, social
environment, socio-economic status, among others – a growing body of
evidence suggests that it could be also, at least in part, an independent
behavioural trait with a specific biological substrate at its basis.
Moreover, studies on AD patients have reported that negative
symptoms, social withdrawal included, cannot be solely accounted for
by depression, co-morbid medical illness, medication exposure, or po-
sitive symptoms (Reichman and Negron, 2001). Studies on SZ patients
have also consistently shown that impairment in social functioning is
largely independent from psychotic symptoms and medications
(Heinssen et al., 2000; Bellack et al., 2004; Arango et al., 2004), al-
though a weak association with positive symptoms has been reported
(Cella et al., 2014). Furthermore, impairment in social functioning is
largely impacted in MD, which is only partly by MD severity (Kitamura
and Suga, n.d.; Galynker et al., 2000). Finally, a psychiatric syndrome
mainly characterized by pure social withdrawal has been recently de-
scribed (i.e. Youth social withdrawal behaviour or “Hikikomori”) and it
is receiving growing attention because it seems to be more common
than previously thought and it does not appear to be limited to specific
cultures (Li and Wong, 2015).
Social withdrawal is a complex behaviour which is the final out-
come of a large series of processes and which is sensitive to more basic
domain deficits. As an example, a focused deficit in attention may
largely impair social withdrawal independent from motivational drives.
Therefore, after a careful analysis of current evidence (Porcelli, in this
issue), we identified attention (Serretti, in this issue), working memory
(Gilmour, in this issue) and sensory processing (Danjou, in this issue) as
possible confounders of social withdrawal variability and decided to
control for their possible deficits in order to reduce background noise.
Interestingly, these are also shared cognitive deficits in SZ, AD and MD
patients (Weintraub et al., 2012; Cohen et al., 2007; Martinez-Aran and
Vieta, 2015; Millan et al., 2012; McIntyre et al., 2013; Lepage et al.,
Fig. 2. In order to provide new classification tools for neuropsychiatric disorders based on quantitative biological parameters, schizophrenia (SZ) and Alzheimer’s disease (AD) patients
with high or low social withdrawal will be selected for a deep phenotyping study. This study will focus on assessing social withdrawal, attention, sensory processing, working memory and
epigenetic biomarkers. In addition, a cross-disorder genome-wide genetic analysis will be performed in the largest world-wide available samples of SZ, AD, and major depression (MD)
patients to identify shared genetic factors potentially related to the common social withdrawal symptom observed in. these disorders. Data integration of genetic and epigenetic studies
through a molecular landscape building approach will lead to new biological substrates and candidate genes for construct validation studies in genetic rodent models. Molecular
landscaping is an unbiased systems biomedicine approach and offers a new platform for data integration. Given that complex traits are modulated by a large number of genetic factors
(Boyle et al., 2017), molecular landscaping provides an effective way to integrate big genetic and other genome-wide data for any complex disease into a model. It involves the application
of gene enrichment, protein–protein interaction, and bioinformatics-based tools. In addition, it is complemented by manual curation and iterative integration of findings from extensive,
thorough and systematic literature evaluations of the top-ranked genes. For more description and examples, see (Poelmans et al., 2011, 2013). Together, these studies will provide new
classification and assessment tools for social and cognitive performance across neuropsychiatric disorders, clinically relevant substrates for treatment development, and predictive,
preclinical animal systems for subsequent neurobiological and pharmacological testing.
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2014), and are known to contribute to interpersonal behaviour (Bowie
et al., 2008).
More precisely, the deficits in working memory and attention found
in drug-naïve and first episode patients with SZ (Mesholam-Gately
et al., 2009; Fatouros-Bergman et al., 2014) are also found in the very
early stages of AD (including in patients with Mild Cognitive Impair-
ment (Weintraub et al., 2012). Interestingly these deficits are also
among the most recognized cognitive impairments seen in patients with
MD (McIntyre et al., 2013). Further, sensory processing – a term that
refers to the way the nervous system receives messages from the senses
and turns them into appropriate motor and behavioural responses
(Hornix, in this issue) is found to be impaired in all three disorders at
the earliest stage of disease (Mesholam-Gately et al., 2009; Weintraub
et al., 2012; McIntyre et al., 2013). Hypofunction of the prefrontal
cortex and over-activity of the anterior cingulate cortex are hypothe-
sized to be correlated with these deficits, reflecting a functional dis-
connection between cortical and subcortical structures (MacQueen
et al., 2003; Waltz et al., 2004; Malykhin et al., 2010; Howes et al.,
2012) and likely involves the catecholamine system (Stahl, 2003;
Howes et al., 2012). Consistent with these overlapping biological pu-
tative factors, cognitive impairments have also been partially associated
with negative symptoms (Cohen et al., 2007; Strauss et al., 2015; Kahn
and Sommer, 2015).
Working memory, attention and sensory processing abnormalities
are thus similar across diagnostic groups and are an ideal complement
to determining a causal model of social withdrawal. In fact, recent data
suggest that interpersonal behaviour could be predicted by processing
speed, attention and working memory, together with executive func-
tions and depressive and negative symptoms (Bowie et al., 2008). In-
terestingly, the effects of attention, working memory and processing
speed seem to be mediated by their effects on social competence.
Therefore, it can be hypothesized that these cognitive deficits induce
impairments in the patient's social competence which eventually results
in high social withdrawal, a hypothesis that receives support from
studies with subjects at high-risk of SZ (Jahshan et al., 2012). In turn,
social withdrawal, and the resulting social isolation, may cause a
worsening of these cognitive deficits (Cacioppo and Hawkley, 2009),
resulting in a vicious circle of progressive worsening of the general
functioning and the patient's quality of life. Therefore, a deep and
combined investigation of these domains may lead to significant ad-
vances in the understanding of the biological underpinning of these
impairments, paving the way for the development of novel treatments
targeted at both social withdrawal and cognitive deficits in SZ, AD, and
MD patients. The similarity of these symptoms suggests that they may
have a common neurobiological basis, but further investigations are
needed to confirm these relationships. If we can design and develop
biomarkers based on quantitative phenotypes that share a common
neurobiological basis, the development of better pre-clinical assays and
treatments will follow (Hengerer, in this issue).
3. Future outlook
3.1. Clinical practice
We have seen that current nosology is mainly based on the historical
effort performed during the seventies mainly aimed to ensure reliability
of psychiatric diagnoses (Spitzer et al., 1975). After many decades it is
still based on reported subjective experiences and patterns of behaviour
of the subject and, though it received some degree of validation from
family and prospective studies, it is still largely unsatisfying (Jablensky,
2016). Prognostic, biologic and treatment validity are in fact moderate
to poor depending of the specific diagnosis. They do not constitute
separate entities such as in other medical fields. This impairs the re-
search of biological determinants as well as the individualization of
treatments and this has prompted the development of the RDoC in-
itiative as mentioned above. Indeed, as an example, bipolar disorder
and schizophrenia have been considered for over a century different
disorders because of their different symptomatology, course, outcome,
partially different treatment response and because to a certain degree
they cluster in families, suggesting a separate biologic background.
However, from a clinical perspective they share many features (such as
psychotic symptoms) and also from a biologic perspective it has been
recently reported that there is a considerable overlap in genetic risk
factors (Cross-Disorder Group of the Psychiatric Genomics Consortium
et al., 2013). This perspective boosted interest in the recent years with
the aim of identifying cross diagnostic biological and clinical constructs
(Kendler, 2013). This is why the focus on the transdiagnostic domain of
social withdrawal feature in the present project is an unprecedented
effort which follows the line of current research with the aim of iden-
tifying a potential independent entity in terms of biologic roots, clas-
sification advances and new targeted treatments.
Current treatments are in fact already becoming cross-diagnostic.
The classical Anatomical Therapeutic Chemical indication based clas-
sification of psychotropic drugs in antidepressants, antipsychotics, an-
xiolytics, hypnotics and mood stabilizers is no more adequate to current
treatments. Quetiapine exemplifies this limitation. It is a hypnotic at
low doses (< 100mg), an antidepressant at intermediate doses
(150–300mg), a mood stabilizer at 300–600mg and an antipsychotic at
higher doses. This is possible because of its pharmacodynamic profile
which targets different systems at different doses. Similarly, different
indications based on dosages apply to sulpiride and pregabalin. The
newly spreading Neuroscience-based Nomenclature (Zohar et al.,
2015), follows this line by defining compounds by their mechanism of
action and their approved efficacy profile across all diagnoses or con-
ditions.
3.2. Drug discovery
The unmet medical need in psychiatry and AD remains to be high. It
is estimated that in any one year 27% of the adult (18–65 years of age)
EU population, approximately 83 million subjects, suffer from at least
one mental disorder. Incidence data also suggest that almost every
second person in the EU is, or has been, affected by mental disorders at
some point in his/her lifetime (Wittchen et al., 2011) much of which is
inadequately treated with the consequence that neuropsychiatric dis-
orders are among the 3 highest causes for disabilities worldwide im-
posing a huge economic burden on societies. Consequently, significant
resources are being devoted to find a disease-modifying treatment for
neuropsychiatric disorders. However, a successful treatment would
ideally prevent rather than reverse the effects of the disease and if so, at
least one if not two generations of neuropsychiatric patients will con-
tinue to require treatments for relief of symptoms such as social with-
drawal.
However, despite the recognized unmet medical need drug dis-
covery efforts for the treatment of neuropsychiatric disorders have been
rather unsuccessful over the past decades. For example, at this stage, no
new treatment for social withdrawal has been registered since the
1990s. As elaborated on above, there is a wide consensus in the field
that this is mainly accounted for by the evident disconnect between
disease classification and diagnosis and an understanding of the un-
derlying pathophysiological causes for diagnosed symptoms.
Implications of this disconnect in the drug discovery process are
manifold. For example, preclinical models and tests unrelated to clin-
ical endpoints and in combination with the lack of biomarkers preclude
a systematic, iterative clinical trial design. Trial populations hetero-
geneous with respect to disease cause and etiologies dilute efficacy
signals and disguise positive outcome. In consequence all contribute to
limited predictability and increased attrition.
PRISM’s new approach is in line with IMI2′s Strategic Research
Agenda, which calls for a ‘reclassification of diseases based on their root
cause’, rather than symptoms, and with the recent NIH/NIMH RDoC
initiative. It will help to address ‘unmet therapeutic needs’ which is a
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key objective of this project. One of the expected outcomes of the
PRISM project is that it will identify the neurobiological underpinnings
of symptoms shared across different diseases. Specifically, it will take
the first steps in achieving this objective by determining the neuro-
biological basis of social withdrawal and cognitive deficits providing a
plausible cause and effects analysis of their relationship in AD and
schizophrenia. Thus it will eventually provide relevant targets for novel
treatments that cut across existing disease boundaries in both psy-
chiatry and neurology. In addition, it will provide biomarkers capable
of bridging the fatal gap between preclinical read-outs and clinical
endpoints, therefore facilitate translation of preclinical findings into
clinical testing as well as refinement of preclinical models and tests by
systematic back-translation from patients. Furthermore, these bio-
markers may enable patient stratification along quantifiable biological
criteria, hence create more homogeneous trial populations. IMI2 also
underlines the need for new biomarkers and methods to support the
stratification of patients to rationalise the way in which clinical trials
are conducted and in particular to predict which patient will respond to
which treatment. PRISM will address these goals by combining new
smartphone technology with the latest imaging techniques to deliver
links between real world data, symptoms and neurobiology. All to-
gether this will lead to the design of more efficient and effective
seamless clinical trials with iterative decision points, which may ulti-
mately yield more rapid and cost-effective drug development and
higher success rates. Finally, PRISM will provide a European-wide
multi-centered clinical trials network based in university centres of
excellence to support drug development in all clinical phases with re-
liable and reproducible data from clinical trials (Bilderbeck, in this
issue).
In summary, the project introduces an unprecedented systematic
approach to link relevant symptoms going across neurodegenerative
and psychiatric conditions with quantifiable biological dimensions. In
this sense it is truly integrative as it embraces all phases of the medi-
cines development cycle reaching from early drug discovery to regis-
tration and market access, i.e. regulatory acceptance of newly identified
biomarkers or indications for drugs improving clinical conditions across
different brain disorders. Thereby the project paves the way into a
paradigm shift for drug discovery and development in neuropsychiatry
and has the potential to serve as a role model for RDoC guided ap-
proaches, including their rapid take-up and acceptance by the scientific
community.
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